title: [The acute effects of inhaled iloprost on hemodynamics and oxygenation in chronic thromboembolic pulmonary hypertension].
abstract: OBJECTIVE
  To evaluate the acute effects of inhaled iloprost on hemodynamics and oxygenation in chronic thromboembolic pulmonary hypertension (CTEPH).
  
  
  METHODS
  A prospective study was made. Eighteen patients with CTEPH were enrolled. At right heart catheterisation, iloprost was inhaled at 20 microg for 10 - 15 min. Compare the value of heart rate (HR), mean blood pressure (mBP), mean pulmonary arterial hypertension (mPAP), right atrium pressure (RAP), pulmonary arterial wedge pressure (PAWP), cardiac output (CO), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2), mixed venous saturation (SvO2), pulmonary shunt fraction (Qs/Qt), alveolar-arterial partial pressure of oxygen [P ( A-a) O2] before to after inhaled iloprost in these patients.
  
  
  RESULTS
  Significant changes (before to after inhalation): mPAP, (53 +/- 11) to (47 +/- 14) mm Hg (P < 0.01); PVR, (821 +/- 194) to (681 +/- 199) dyn x s x cm(-5) (P < 0.01); RAP, (10 +/- 6) to (7 +/- 6) mm Hg (P < 0.01). However, HR, PAWP, mBP, CO and SVR had no significant changes. At the same time, inhaled iloprost significantly decreased PaO2 from (58 +/- 11) to (52 +/- 6) mm Hg (P < 0.01) and increased Qs/Qt from (27 +/- 11)% to (33 +/- 9)% (P < 0.01)and P(A-a) O2 from (86 +/-39) to (93 +/- 38) mm Hg (P < 0.01).
  
  
  CONCLUSIONS
  Inhaled iloprost might instantly improve hemodynamics in CTEPH, but at the same time it increased arteriovenous shunts which resulted in lower PaO2.
authors.affiliation: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Diseases, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Luo
authors.forename: Yuan-Hua
authors.initials: YH
authors.lastname: Yang
authors.forename: Na
authors.initials: N
authors.lastname: Cui
authors.forename: Wan-Mu
authors.initials: WM
authors.lastname: Xie
authors.forename: Zhen-Guo
authors.initials: ZG
authors.lastname: Zhai
authors.forename: Zhan-Hong
authors.initials: ZH
authors.lastname: Ma
authors.forename: Chen
authors.initials: C
authors.lastname: Wang
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D016285:Iloprost / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood*; D010313:Partial Pressure; D011446:Prospective Studies; D011659:Pulmonary Gas Exchange; D011669:Pulmonary Wedge Pressure / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D014665:Vasodilator Agents; D016285:Iloprost; D010100:Oxygen